Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Are These Five Stocks Rallying on Wednesday?

Page 1 of 2

Another red day on Wall Street with all three indices declining by more than 1%, but shares of Mobileye NV (NYSE:MBLY), TASER International, Inc. (NASDAQ:TASR), Barrick Gold Corporation (USA) (NYSE:ABX), Yamana Gold Inc. (USA) (NYSE:AUY), and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) are registering gains. So let’s take a closer look at the developments that sent these stocks higher and see the hedge fund sentiment towards them.

Let’s first take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research, we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith (and money) in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 53 percentage points, returning over 102% (read the details here). Follow the smart money into only their best investment ideas all while avoiding their high fees.

The first on the list is Mobileye NV (NYSE:MBLY), whose stock is well in the green on news regarding the development of a new technology, Road Experience Management (REM), which, through real-time data source location and other high-definition data, will provide information for fully-autonomous driving. Moreover, the company has signed an agreement with Volkswagen AG to include the new technology into the Volkswagen’s fleet. It also plans to integrate REM into existing program launches of General Motors.

“We leveraged advanced artificial intelligence, used for creating environmental models from camera input, in order to create maps based on local coordinate systems while requiring very low bandwidth,” Prof. Amnon Shashua, co-founder, chairman and Chief Technology Officer of Mobileye was quoted as saying in a statement.

Among the funds we follow, 32 reported long positions in Mobileye NV as of the end of September, down by seven funds from a quarter earlier.

Second in our list is TASER International, Inc. (NASDAQ:TASR), whose shares are up by around 5.5% today after the analysts at JPMorgan Chase upgraded the company to ‘Overweight’ from ‘Neutral’, while maintaining the price target at $25 per share (a 40% upside potential from the current price and 70% higher than the consensus price target). The analyst Mark Strouse added that in terms of the Sum-Of-The-Parts (SOTP) Valuation, the $25 price target includes $20 for the weapons business, with the remainder – for the company’s video segment. The upgrade is based on a proper risk-reward relationship, as well as new contracts.

During the third quarter, TASER International, Inc. (NASDAQ:TASR) registered a decrease in popularity among the funds we track, with 15 investors holding long positions at the end of September, versus 18 funds a quarter earlier. Peter Rathjens, Bruce Clarke and John Campbell‘s Arrowstreet Capital is the largest shareholder of the company among the investors we follow, with 1.39 million shares valued at $30.7 million as of the end of the third quarter.

Follow Taser International Inc (NASDAQ:TASR)
Trade (NASDAQ:TASR) Now!

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!